The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Excessive Daytime Sleepiness Market?
The market size for excessive daytime sleepiness has experienced robust expansion in recent years. This market is projected to expand from $5.39 billion in 2025 to $5.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. Historically, this expansion has been driven by factors such as the increasing occurrence of sleep disorders, a heightened understanding of sleep health’s effects, the development of sleep clinic facilities, the accessibility of pharmaceutical agents that promote wakefulness, and the broadening of diagnostic sleep testing capabilities.
The market for excessive daytime sleepiness is anticipated to experience substantial expansion over the upcoming years. It will grow to $8.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. This projected growth can be linked to several factors, including a heightened need for customized sleep treatment options, greater incorporation of digital therapeutics into sleep management, wider acceptance of remote patient monitoring, an increasing emphasis on preventive sleep health, and expanded investment in sleep medicine research. Key developments expected during this period involve a rise in the use of wearable devices for sleep monitoring, an increase in combination therapy approaches, broader availability of home-based sleep disorder management, a stronger focus on early detection and screening initiatives, and improved integration of digital platforms for sleep health.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33109&type=smp
Which Major Factors Are Contributing To The Development Of The Excessive Daytime Sleepiness Market?
The rising prevalence of obstructive sleep apnea (OSA) is anticipated to drive the growth of the excessive daytime sleepiness (EDS) market. Obstructive sleep apnea, a sleep disorder characterized by repeated pauses in breathing from upper airway blockage, is seeing increased prevalence, primarily due to rising obesity rates that narrow the airway. As excessive daytime sleepiness is a common and often persistent symptom of OSA, it creates a demand for targeted therapeutic and management solutions. For instance, the National Library of Medicine, a US-based medical library, projected in August 2026 that approximately 76.6 million adults aged 30–69 in the United States are expected to be affected by obstructive sleep apnea by 2050. Consequently, the increasing prevalence of obstructive sleep apnea is driving the expansion of the excessive daytime sleepiness market.
How Is The Excessive Daytime Sleepiness Market Examined Through Segment Analysis?
The excessive daytime sleepiness market covered in this report is segmented –
1) By Treatment Type: Pharmacological Treatment; Behavioral Therapy; Continuous Positive Airway Pressure Therapy; Lifestyle Modification Programs; Combination Therapies
2) By Diagnosis Method: Polysomnography; Multiple Sleep Latency Test; Actigraphy; Clinical Evaluation; Questionnaire Based Assessments
3) By Type Of Disorder: Narcolepsy; Obstructive Sleep Apnea; Insomnia; Circadian Rhythm Disorders; Idiopathic Hypersomnia; Restless Legs Syndrome; Other Type Of Disorders
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Sleep Clinics; Ambulatory Surgical Centers; Home Care Settings
Subsegments:
1) By Pharmacological Treatment: Wake Promoting Medications; Central Nervous System Stimulant Medications; Dopamine Reuptake Inhibitor Medications; Histamine Receptor Modulating Medications
2) By Behavioral Therapy: Cognitive Behavioral Therapy For Sleep; Sleep Hygiene Education Programs; Stimulus Control Therapy; Sleep Restriction Therapy
3) By Continuous Positive Airway Pressure Therapy: Fixed Pressure Airway Therapy; Auto Adjusting Airway Therapy; Bilevel Airway Therapy; Adaptive Pressure Support Therapy
4) By Lifestyle Modification Programs: Sleep Schedule Regulation Programs; Diet And Nutrition Management Programs; Physical Activity And Exercise Programs; Stress Management And Relaxation Programs
5) By Combination Therapies: Medication And Behavioral Therapy Combinations; Airway Therapy And Lifestyle Modification Combinations; Medication And Airway Therapy Combinations; Integrated Multimodal Treatment Approaches
Which Trends Are Influencing The Expansion Of The Excessive Daytime Sleepiness Market?
Leading companies in the excessive daytime sleepiness market are concentrating on developing innovative remedies, such as central nervous system depressants, to enhance wakefulness and improve the quality of life for patients. A central nervous system depressant is a substance that decreases nervous system activity, resulting in sedation, calmness, or sleep. For example, in September 2025, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, obtained approval from the FDA for sodium oxybate oral solution, which directly addresses excessive daytime sleepiness (EDS) in narcolepsy patients. This product improves treatment continuity by facilitating virtual specialist consultations, remote prescription fulfillment, and greater patient outreach in underserved areas, with the aim of expanding access, increasing affordability, and integrating established pharmacotherapy with contemporary digital and telehealth-driven care models for excessive daytime sleepiness.
Who Are The Major Companies Operating In The Excessive Daytime Sleepiness Market?
Major companies operating in the excessive daytime sleepiness market are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cleveland Clinic, EisAI Co. Ltd, Jazz Pharmaceuticals plc., Emory Healthcare Inc., Alkermes plc., Fisher & Paykel Healthcare Corporation Limited, Harmony Biosciences Holdings Inc., Medanta, Axsome Therapeutics Inc., Compumedics Limited, BIOPROJET, Apnimed Inc., Nox Health Inc., Somnogen Canada Inc., Suven Life Sciences Limited, Theranexus, XWPharma, NLS Pharmaceutics AG.
Access The Complete Excessive Daytime Sleepiness Market Report:
https://www.thebusinessresearchcompany.com/report/excessive-daytime-sleepiness-market-report
Which Region Leads The Excessive Daytime Sleepiness Market By Size?
North America was the largest region in the excessive daytime sleepiness market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the excessive daytime sleepiness market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Excessive Daytime Sleepiness Market Report for Deeper Competitive Insights
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model